Dr Reddy's Laboratories PE Ratio 2012-2026 | RDY
Current and historical p/e ratio for Dr Reddy's Laboratories (RDY) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Dr Reddy's Laboratories PE ratio as of September 17, 2026 is 24.85.
| Dr Reddy's Laboratories PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-09-17 | 12.19 | 29.73 | |
| 2026-06-30 | 14.35 | $0.41 | 34.99 |
| 2026-03-31 | 13.71 | $0.55 | 24.93 |
| 2025-12-31 | 13.90 | $0.92 | 15.19 |
| 2025-09-30 | 13.84 | $0.95 | 14.53 |
| 2025-06-30 | 14.79 | $0.79 | 18.72 |
| 2025-03-31 | 12.98 | $0.79 | 16.43 |
| 2024-12-31 | 15.54 | $0.63 | 24.84 |
| 2024-09-30 | 15.63 | $0.62 | 25.05 |
| 2024-06-30 | 14.18 | $0.80 | 17.68 |
| 2024-03-31 | 13.65 | $0.80 | 17.02 |
| 2023-12-31 | 12.95 | $0.74 | 17.45 |
| 2023-09-30 | 12.45 | $0.73 | 17.13 |
| 2023-06-30 | 11.57 | $0.68 | 17.02 |
| 2023-03-31 | 10.44 | $0.66 | 15.82 |
| 2022-12-31 | 9.49 | $0.54 | 17.68 |
| 2022-09-30 | 9.60 | $0.47 | 20.50 |
| 2022-06-30 | 9.74 | $0.46 | 21.08 |
| 2022-03-31 | 9.80 | $0.37 | 26.20 |
| 2021-12-31 | 11.50 | $0.45 | 25.41 |
| 2021-09-30 | 11.46 | $0.34 | 33.55 |
| 2021-06-30 | 12.56 | $0.30 | 41.30 |
| 2021-03-31 | 10.49 | $0.30 | 34.49 |
| 2020-12-31 | 12.18 | $0.32 | 37.48 |
| 2020-09-30 | 11.88 | $0.22 | 52.88 |
| 2020-06-30 | 8.77 | $0.29 | 30.44 |
| 2020-03-31 | 6.67 | $0.31 | 21.38 |
| 2019-12-31 | 6.71 | $0.29 | 23.46 |
| 2019-09-30 | 6.27 | $0.46 | 13.50 |
| 2019-06-30 | 6.15 | $0.36 | 16.90 |
| 2019-03-31 | 6.65 | $0.33 | 20.27 |
| 2018-12-31 | 6.19 | $0.30 | 20.50 |
| 2018-09-30 | 5.68 | $0.28 | 20.06 |
| 2018-06-30 | 5.24 | $0.25 | 20.96 |
| 2018-03-31 | 5.32 | $0.18 | 29.23 |
| 2017-12-31 | 6.11 | $0.19 | 31.95 |
| 2017-09-30 | 5.81 | $0.21 | 27.35 |
| 2017-06-30 | 6.81 | $0.21 | 32.12 |
| 2017-03-31 | 6.49 | $0.22 | 29.23 |
| 2016-12-31 | 7.32 | $0.16 | 44.67 |
| 2016-09-30 | 7.50 | $0.18 | 40.93 |
| 2016-06-30 | 8.24 | $0.26 | 31.68 |
| 2016-03-31 | 7.26 | $0.35 | 20.52 |
| 2015-12-31 | 7.44 | $0.45 | 16.65 |
| 2015-09-30 | 10.27 | $0.45 | 22.83 |
| 2015-06-30 | 8.85 | $0.43 | 20.68 |
| 2015-03-31 | 9.13 | $0.42 | 21.75 |
| 2014-12-31 | 8.07 | $0.42 | 19.40 |
| 2014-09-30 | 8.41 | $0.43 | 19.64 |
| 2014-06-30 | 6.86 | $0.45 | 15.25 |
| 2014-03-31 | 6.98 | $0.42 | 16.54 |
| 2013-12-31 | 6.52 | $0.45 | 14.56 |
| 2013-09-30 | 6.01 | $0.41 | 14.65 |
| 2013-06-30 | 5.98 | $0.38 | 15.73 |
| 2013-03-31 | 5.11 | $0.38 | 13.45 |
| 2012-12-31 | 5.26 | $0.34 | 15.47 |
| 2012-09-30 | 4.88 | $0.38 | 12.83 |
| 2012-06-30 | 4.69 | $0.36 | 13.03 |
| 2012-03-31 | 5.42 | $0.35 | 15.48 |
| 2011-12-31 | 4.61 | $0.35 | 13.18 |
| 2011-09-30 | 4.67 | $0.31 | 15.07 |
| 2011-06-30 | 5.38 | $0.31 | 17.36 |
| 2011-03-31 | 5.70 | $0.30 | 19.00 |
| 2010-12-31 | 5.65 | $0.26 | 21.73 |
| 2010-09-30 | 4.92 | $0.04 | 123.12 |
| 2010-06-30 | 4.72 | $0.02 | 235.78 |
| 2010-03-31 | 4.28 | $0.02 | 214.21 |
| 2009-12-31 | 3.67 | $-0.24 | 0.00 |
| 2009-09-30 | 2.96 | $-0.06 | 0.00 |
| 2009-06-30 | 2.56 | $-0.08 | 0.00 |
| 2009-03-31 | 1.42 | $-0.10 | 0.00 |
| 2008-12-31 | 1.48 | $0.15 | 9.98 |
| 2008-09-30 | 1.68 | $0.08 | 20.50 |
| 2008-06-30 | 2.34 | $0.12 | 19.19 |
| 2008-03-31 | 2.17 | $0.14 | 15.75 |
| 2007-12-31 | 2.73 | $0.11 | 25.24 |
| 2007-09-30 | 2.46 | $0.31 | 7.92 |
| 2007-06-30 | 2.41 | $0.35 | 6.93 |
| 2007-03-31 | 2.46 | $0.33 | 7.36 |
| 2006-12-31 | 2.72 | $0.33 | 8.14 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $9.749B | $3.580B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |